We are very pleased to announce the award of a Small Business Innovation Research (SBIR) Phase I grant from the National Institute of Diabetes and...
MAX BioPharma receives an NIH SBIR Phase I award in support of its NASH program
read more
News and Events
MAX BioPharma Announces Update to its Liver Fibrosis Program
MAX BioPharma, Inc. recently published an article describing its anti-tumorigenic oxysterol lead compound, Oxy210, in the peer-reviewed...
MAX BioPharma Announces Update to its Oncology Program and Lead Drug Candidates
MAX BioPharma, Inc. recently published two articles describing its anti-tumorigenic oxysterol lead compounds in the peer-reviewed journal, Cells....
MAX BioPharma Publishes Follow Up Manuscript on its Oncology Program
MAX BioPharma scientists publish new paper titled "Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that...
MAX BioPharma reports on novel oxysterol drug candidate for cancer
MAX BioPharma scientists publish new paper titled "Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an...